SCHEMBL22719775

SCHEMBL22719775

C=C(C)c1cc(S(=O)(=O)NC)ccc1Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.56
▸ AKR1C3 P42330 2/20 0.52
▸ AKR1C2 P52895 2/20 0.52
▸ MPO P05164 4/20 0.49
▸ IDH2 P48735 2/20 0.48
▸ RXFP1 Q9HBX9 2/20 0.47
▸ TNNI3K Q59H18 4/20 0.47
▸ FFAR1 O14842 1/20 0.46
▸ CDK1 P06493 1/20 0.46
▸ CCNB1 P14635 1/20 0.46
▸ CCNA2 P20248 1/20 0.46
▸ CDK2 P24941 1/20 0.46
▸ CDK7 P50613 1/20 0.46
▸ CCNH P51946 1/20 0.46
▸ CCNA1 P78396 1/20 0.46
▸ FFAR4 Q5NUL3 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ MMP1 P03956 1/20 0.46
▸ MMP2 P08253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29505053 1.00 MAPT (0.56) MAPTAKR1C3AKR1C2MPOIDH2
SCHEMBL29438887 0.90 AKR1C3 (0.58) MAPTAKR1C3AKR1C2MPOIDH2
SCHEMBL22718236 0.90 AKR1C3 (0.58) MAPTAKR1C3AKR1C2MPOIDH2
SCHEMBL22719612 0.84 YAP1 (0.65) MAPTAKR1C3AKR1C2MPOIDH2
SCHEMBL29505020 0.84 YAP1 (0.65) MAPTAKR1C3AKR1C2MPOIDH2
SCHEMBL20779650 0.82 MAPT (0.62) MAPTAKR1C3AKR1C2MPOIDH2
SCHEMBL29438860 0.81 MAPT (0.51) MAPTAKR1C3AKR1C2MPOIDH2
SCHEMBL22718119 0.81 MAPT (0.51) MAPTAKR1C3AKR1C2MPOIDH2
SCHEMBL22719577 0.81 MAPT (0.57) MAPTAKR1C3AKR1C2MPOIDH2
SCHEMBL20779877 0.74 MAPT (0.55) MAPTAKR1C3AKR1C2IDH2TNNI3K

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11925651-B2 TEAD inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-03-12 — — US disclosed
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2023-05-11 — — US disclosed
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2023-05-11 — — US disclosed
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2023-05-11 — — US disclosed
US-11458149-B1 TEAD inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-10-04 — — US disclosed
EP-3976192-A1 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2022-04-06 — — EP disclosed
WO-2020243423-A1 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed
WO-2020243423-A1 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 MAPT 507/4885AKR1C3 2451/4885AKR1C2 2578/4885
US-11925651-B2 TEAD inhibitors and uses thereof TEAD2, TEAD3, TEAD4 MAPT 507/4885AKR1C3 2451/4885AKR1C2 2578/4885
US-11458149-B1 TEAD inhibitors and uses thereof TEAD2, TEAD3, TEAD4 MAPT 507/4885AKR1C3 2451/4885AKR1C2 2578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback